blood tests gradually normalized. Complete resolution of the ERD was evident (Figure 1b). VA improved to 6/36.
Sir, Liver failure following antituberculosis (ATT) chemotherapy for presumed tuberculous uveitis
We read with great interest the paper by Manousaridis et al, 1 which adds to the publication by Sanghvi et al, 2 with respect to presumed tuberculous (TB) uveitis in the United Kingdom, and we would commend both sets of authors for these well-presented case series. In the latter 2 it was recommended that a full 6-month course of Anti-TB therapy (ATT) be commenced in all patients with uveitis and latent TB, in whom other causes of uveitis have been ruled out. We present a case of acute liver failure secondary to ATT in one such patient.
Case report
A 41-year-old Indian lady presented to Leicester Royal Infirmary Eye Casualty with gradual reduction in vision with floaters and was found to have bilateral granulomatous pan-uveitis. The best-corrected visual acuity was 6/36 in both eyes, and there were multiple choroidal tubercles ( Figure 1 ) with leakage on fluorescein angiography. Quantiferon-TB gold testing was positive.
The Infectious Diseases Unit found no evidence of other active systemic TB and the patient was started on Rifater (rifampicin, isoniazid, pyrazinamide), Moxifloxacin 400 mg, and Pyridoxine 10 mg. After 28 days, the patient was admitted to a tertiary liver centre ITU with acute liver failure presumed secondary to ATT and subsequently developed severe autoimmune haemolysis presumed secondary to rifampicin. The ATT was stopped and the patient recovered. The patient declined any further ATT. The visual acuity at her last visit was 6/9 in each eye with low-dose topical steroid.
Comment
Hepatotoxicity is the most common iatrogenic disease in TB 3 with an incidence between 1 and 10% worldwide, 4, 5 and 4% in the United Kingdom. 6 The benefits of ATT clearly outweigh the risks for active TB. However, this is not true in cases of latent TB and NICE guidance highlights those patient groups most likely to benefit from ATT. 7 In the series of patients reported, 1,2 those who benefited most in terms of visual acuity from ATT had active TB and received systemic or periocular steroid. Furthermore, ATT may not be curative of the uveitis. 3 We therefore recommend some caution when considering ATT in patients with presumed TB uveitis and latent TB.
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Sir, Reply to Wakefield and Kumar
We would like to thank Wakefield and Kumar 1 for their useful comments. It is true that the exact association between latent TB and uveitis is not known. In our series, all patients with presumed intraocular TB and active TB elsewhere received standard antituberculous therapy (ATT). Patients with presumed intraocular TB and latent TB were generally offered ATT, but this was done after careful consideration of individual risk/benefit. Indeed, as we state in our article, two patients with latent TB and presumed intraocular TB received no ATT, because we estimated that the risks of treatment outweighed any potential benefit in them. 2 ATT has well-recognized systemic and ocular adverse effects. On the other hand, it is known that ATT can eliminate latent TB and decrease a person's lifetime risk of developing active TB by 90%. 3 Moreover, administering corticosteroid or immunosuppressive therapy for severe intraocular inflammation without the coverage of ATT may cause re-activation of systemic TB, resulting in severe disseminating TB or even panophthamlitis. 4, 5 In a large series of patients with presumed intraocular TB and latent TB combination treatment with corticosteroids and ATT reduced the risk of developing recurrence of the uveitis by approximately two-thirds compared to 
